VIDEO: Tildrakizumab shows ‘increasing efficacy and improvement’ for psoriasis

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor tildrakizumab from the Maui Derm 2024 meeting.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed a phase 4 study evaluating the real-world effectiveness of tildrakizumab (Ilumya, Sun Dermatology) over 64 weeks.

“What was found is starting right at the first dose and going all the way to the end, there was increasing efficacy and improvement in patients throughout, suggesting that what we’ve seen in the Phase 3 trials is really being mirrored in a real-world population,” Chovatiya said.